ClinicalTrials.gg
Active, not recruitingNCT06072131CRESCENDOUpdated Oct 15, 2026

To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL

A Phase 3 interventional study of Belinostat Injection and Pralatrexate Injection in Peripheral T Cell Lymphoma, sponsored by Acrotech Biopharma Inc.. Active, not recruiting at 58 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Acrotech Biopharma Inc. (part of Aurobindo Pharma) · Phase 3, Interventional, and Treatment

Updated Oct 15, 2026Now Active, not recruiting1 site added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
504
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing pralatrexate in Lymphoma, T-Cell, Peripheral — none open to participants now, 1 under way, 1 of them phase 3. pralatrexate · Lymphoma, T-Cell, Peripheral.

Planned enrollment
Largest of 11
504 · median 48
Started
2023
the only one that year
Phase 3
3 of 11
none open now
Registered
11th of 11
by date
Lead sponsor
5 of 11
Acrotech Biopharma Inc.

Among the 11 studies testing pralatrexate in Lymphoma, T-Cell, Peripheral, this one has the largest planned enrollment, is the only one that started in 2023, is one of 3 in phase 3, and was the 11th registered.

Lymphoma, T-Cell, Peripheral

372 studies on the registry are indexed under Lymphoma, T-Cell, Peripheral; 110 are open to participants now.

Browse Lymphoma, T-Cell, Peripheral studies →

Open to participants now

None of the 11 studies testing pralatrexate in Lymphoma, T-Cell, Peripheral is open now. The open studies under Lymphoma, T-Cell, Peripheral, anywhere →

About pralatrexate

pralatrexate: first FDA approval 2009 (FOLOTYN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 76 Lymphoma, T-Cell, Peripheral studies recruiting now, 30 (39%) set no upper age limit and 38 (50%) stop at 75 or younger; 5 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing pralatrexate in Lymphoma, T-Cell, Peripheral as a file.
02

Study summary

Part 1: This is a 5 Arm study primarily to determine the best dose out of the two dose levels of Belinostat and Pralatrexate combined with CHOP/COP in newly diagnosed PTCL patients based on Safety for part 2 study.

Part 2 (Efficacy and Safety): This is a 3 Arm study. Patients with previously untreated PTCL will be randomized 1:1:1 into 1 of 3 treatment groups: 2 experimental treatment groups (Bel-CHOP or Fol-COP) or 1 active comparator treatment group (CHOP). Patients will be treated for up to 6 cycles. The primary objective is to compare the Progression Free Survival of patients with newly diagnosed PTCL treated for up to 6 cycles with Beleodaq (belinostat) in combination with CHOP (Bel-CHOP) or Folotyn (pralatrexate injection) in combination with COP (Fol-COP) to CHOP alone.

Read the detailed description

Study Design and Treatment Plan:

Part 1: Dose Finding

It is a randomized, open label, multicenter study in patients with PTCL who have not been previously treated and the control arm is CHOP, COP, is the CHOP regimen without Doxorubicin (H). Two investigational agents are separately added to C(H)OP, Belinostat for Bel-CHOP and Pralatrexate for FOL-COP. In this first part, each investigational arm will have two dose levels which will be compared with CHOP as reference. Treatment will be randomized in five arms:

  1. Group 1a (Bel-CHOP) Belinostat 600 mg/m2
  2. Group 1b (Bel-CHOP) Belinostat 1000 mg/m2
  3. Group 2a (Fol-COP) Pralatrexate 20 mg/m2
  4. Group 2b (Fol-COP) Pralatrexate 30 mg/m2
  5. Group 3 for CHOP alone. Analysis will be done when 75 patients have received their planned treatment cycles to evaluate treatment compliance.

Approximately 20 patients will be enrolled into each group and receive at least one cycle of drug thus 15 patients are expected to be evaluated with their planned treatment of 6 cycles completed. The safety data will be evaluated to select the proper dose for Belinostat -CHOP and Pralatrexate-COP for the Part 2 study.

Part 2: Efficacy and Safety

It is a randomized, open-label, multicenter study in newly diagnosed PTCL patients. This is a three arm study and 143 patients will enroll in each arm. Patients will be randomized in a balance manner (1:1:1) into 1 of 3 treatment groups and treated for up to 6 cycles:

Group 1: (Bel-CHOP): Belinostat at the dose determined from Part 1 (600 or 1000 mg/m2) to be administered on Day 1 by 30 min intravenous (IV) infusion once daily for 5 days; CHOP will also be administered starting on Day 1 within 15 min (±5 min) after the end of the belinostat infusion at the doses shown below for Group 3, with cycles repeated every 21 days for up to 6 cycles

Group 2: (Fol-COP): Pralatrexate at the dose determined from part 1 (20 or 30 mg/m2) is to be administered on Day 1 and Day 8 as an IV push over 3 to 5 min; CHOP will also be administered starting on Day 1 within 15 min (±5 min) after the end of the pralatrexate administration at the doses shown below for Group 3, with cycles repeated every 21 days for up to 6 cycles. COP combination refers to CHOP without Doxorubicin (H).

Group 3: (CHOP): Combination chemotherapy to be administered starting on Day 1 at the doses shown below, with cycles repeated every 21 days for up to 6 cycles

  • Cyclophosphamide 750 mg/m2 IV, Day 1
  • Doxorubicin 50 mg/m2 IV, Day 1 (limit lifetime cumulative dose to \<550 mg/m² to reduce risk of cardiotoxicity)
  • Vincristine 1.4 mg/m2 (maximum 2 mg) IV, Day 1
  • Prednisone 100 mg orally (PO) daily, Day 1 (after the end of the belinostat or pralatrexate administration for Groups 1 and 2) to Day 5

Randomization will be stratified on:

  • Histology (nodal, extra-nodal)
  • Prognostic Index for T-Cell Lymphoma (Group 1 or 2 vs 3 or 4)
  • Region (US, ex-US)

The study duration will include up to a 28-day screening period, a 6-cycle treatment period (18 weeks), follow-up until progression, an End-of-Treatment Visit at least 30 days after the last dose of study treatment, and long-term survival follow-up for patients by phone every 6 months thereafter until a 5-year median follow-up of the population is reached. Patients discontinuing the study for other reasons than progression will have the same long-term follow-up for OS analysis. Tumor assessments will be performed every 3 cycles (i.e., 9 weeks) on Cycle 4 Day 1 and End-of-Treatment Visit during treatment, then every 3 months for 3 years for patients with complete response (CR), partial response (PR), or stable disease, and every 6 months thereafter until disease progression or death

03

Conditions studied

  • Peripheral T Cell Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient with newly diagnosed, untreated histology-proven PTCL based on local pathology review who is eligible for receiving, Belinostat, Pralatrexate, and CHOP. Pathology material must be available at the site for each patient before enrollment so that it can be sent to the Sponsor (or designee) for later confirmation. The following subtypes, as defined by the updated World Health Organization (WHO) classification, may be included. This information should be available for eligibility:

    1. Pathology subtype:

      • Peripheral T-cell lymphoma, not otherwise specified
      • Angioimmunoblastic T-cell lymphoma
      • Anaplastic lymphoma kinase (ALK)-negative anaplastic large-cell lymphoma (ALCL) patients are eligible only if Brentuximab Vedotin (BV) is not commercially approved for use, not available in the country or patient is to receive BV.
      • Follicular T-cell lymphoma
      • Others: Extra-nodal natural killer/T-cell lymphoma, nasal type; enteropathy-associated T-cell lymphoma; hepatosplenic T-cell lymphoma; and subcutaneous panniculitis-like T-cell lymphoma
    2. CD30 expression and T-cell Follicular Helper (TFH) phenotype status must be available for documentation.
  2. Patient has at least 1 site of according to Response Evaluation Criteria in Lymphoma (RECIL) 2017 criteria as assessed by the local Investigator (Appendix 3)
  3. Patient has an performance (ECOG) status ≤2
  4. For Part 1 (Dose Finding) - Patient has adequate hematological, hepatic, and renal function as defined by:

    1. ≥ 1.5 × 10⁹/L or ≥ 1.0 × 10⁹/L if evidence of bone marrow involvement
    2. count ≥100×10⁹/L or ≥ 75×10⁹/L if evidence of bone marrow involvement
    3. Total ≤1.5 mg/dL
    4. (AST)/serum glutamic-oxaloacetic transaminase (SGOT), alanine aminotransferase (ALT)/serum glutamic-pyruvic transaminase (SGPT) ≤ 3× (ULN; AST/ALT ≤5×ULN if documented hepatic involvement with lymphoma)
    5. Calculated of ≥ 60 mL/min
  5. Part 2 (Efficacy and Safety) - disease related hypoplasia, hepatological or renal dysfunction can be included if any of the treatment groups can be administered based on package insert recommendation with the following restrictions:

    1. Absolute neutrophil count ≥ 1.5 × 10⁹/L or ≥ 1.0 × 10⁹/L if evidence of bone marrow involvement
    2. Platelet count ≥100×10⁹/L or ≥ 75×10⁹/L if evidence of bone marrow involvement
    3. Total bilirubin ≤1.5 mg/dL
    4. Aspartate aminotransferase (AST)/serum glutamic-oxaloacetic transaminase (SGOT), alanine aminotransferase (ALT)/serum glutamic-pyruvic transaminase (SGPT) ≤ 3 x the upper limit of normal (ULN; AST/ALT ≤5×ULN if documented hepatic involvement with lymphoma)
    5. Calculated creatinine clearance of ≥ 60 mL/min
  6. UGT1A1 genotype has been characterized (see Belinostat dose modifications if abnormal) and must be available for documentation.
  7. Patient must be willing and capable of giving written and must be able to adhere to dosing and visit schedules and meet all study requirements
  8. Patient (male or female) is at least 18 years of age at the time of informed consent
  9. Patient is willing to practice 2 forms of , one of which must be a barrier method, from study entry until at least 6 months after the last dose of study treatment.
  10. Females of must have a negative urine pregnancy test within 4 weeks prior to the first day of study treatment. Females who are for at least 1 year (defined as more than 12 months since last menses) or are surgically sterilized do not require this test.

Exclusion criteria

Exclusion Criteria:

A patient will not be eligible for inclusion if ANY of the criteria listed below apply:

  1. Patients with a diagnosis of:

    1. Precursor T-cell lymphoma or leukemia
    2. Adult T-cell lymphoma/leukemia
    3. T-cell prolymphocytic leukemia
    4. T-cell large granular lymphocytic leukemia
    5. Primary cutaneous type ALCL
    6. Cutaneous T-cell lymphoma (mycosis fungoides/Sezary syndrome)
    7. ALCL if they can be treated with Brentuximab Vedotin (BV)
  2. Patients taking drugs which are potent UGT1A1 inhibitors must discontinue one week before randomization; drug can be resumed if the treatment doesn't include belinostat
  3. Patient with an active concurrent /life-threatening disease with the exception of non melanoma skin tumors and in situ cervical cancer if they have received treatment resulting in complete resolution of the cancer and currently have no clinical, radiologic, or laboratory evidence of active or recurrent disease. If there is a history of prior malignancies/life-threatening diseases, the patient must be disease free for at least 5 years
  4. Prior histone deacetylase (HDAC) inhibitor or pralatrexate therapy
  5. Any known cardiac abnormalities such as baseline prolongation of /corrected QT (QTc) interval (i.e. demonstration of a QTc interval >450 msec); long QT syndrome; myocardial infarction within 6 months prior to starting study; history of significant cardiovascular disease; the required use of a concomitant medication that may cause Torsades de Pointes
  6. Patient with uncontrolled hypertension
  7. Patients status on the following:

    1. Has a known -positive diagnosis with uncontrolled and detectable viral load
    2. Has or virus diagnosis with uncontrolled and detectable viral load or immunological evidence of chronic active disease
  8. Patient with central nervous system
  9. Patient with an active uncontrolled infection, underlying medical condition, laboratory abnormality, or other serious illness that would impair the ability of the patient to receive protocol treatment
  10. Patient who has used any drugs, biologics, or devices within 28 days prior to study treatment or plans to use any of these during the course of the study
  11. Patient with a known history of drug or alcohol abuse
  12. Pregnant or breastfeeding women
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
504 participants (estimated)

Study arms

  • Active comparator
    Group 1a

    Group 1a Belinostat 600 mg/m2 + CHOP

    Drug: Belinostat Injection · Drug: CHOP

  • Active comparator
    Group 1b

    Group 1b Belinostat 1000 mg/m2 + CHOP

    Drug: Belinostat Injection · Drug: CHOP

  • Active comparator
    Group 2a

    Group 2a Pralatrexate 20 mg/m2 + COP

    Drug: Pralatrexate Injection · Drug: COP

  • Active comparator
    Group 2b

    Group 2b Pralatrexate 30 mg/m2 + COP

    Drug: Pralatrexate Injection · Drug: COP

  • Active comparator
    Group 3

    CHOP

    Drug: CHOP

Interventions

  • Belinostat 600 mg/m2 or 1000 mg/m2 along with CHOP is given in each cycle

    Also known as: Beleodaq®

  • Pralatrexate 20 mg/m2 or 30 mg/m2 along with COP is given in each cycle

    Also known as: Folotyn®

  • DrugCHOP

    Drug pages: Cyclophosphamide · Doxorubicin · Vincristine · Prednisone

    CHOP is the comparator arm

    Also known as: Cyclophosphamide, Hydroxydaunorubicin (doxorubicin), Oncovin (vincristine), and Prednisone

  • DrugCOP

    COP is given in combination with Pralatrexate

    Also known as: Cyclophosphamide, Oncovin (vincristine), and Prednisone

06

What researchers measure

Primary outcomes

  1. PFS

    Progression-free survival is determined from randomization to the first documented Progression of Disease or death, whichever occurs first.

    Time frame: 4.5 years

Secondary outcomes

  1. Overall survival

    It is the time from randomization to the death

    Time frame: 8 years

07

Study locations

58 sites
08

References and documents

Individual participant data

Plan to share: No — Data Review Committee: An Independent Data Monitoring Committee (IDMC) will be established for the purpose of reviewing patient safety and the results of the futility analysis. The IDMC will convene after the enrollment and analysis of Part 1 to evaluate safety and preliminary efficacy. The IDMC will recommend the selected dose for Belinostat and Pralatrexate. The IDMC will also convene after the analysis of 120 events, in Part 2, to state whether the study can continue. This Committee will review review study data will adjudicate tumor response and the date of onset of disease progression in all patients at the end of the study. All scans will be centrally reviewed and the primary analysis of PFS will be conducted on these results.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2023 (actual). Primary completion is estimated for Jul 2030, 81 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2023
First posted
Oct 10, 2023
StartActual
Oct 4, 2023
Primary completionEst.
Jul 2030
CompletionEst.
Nov 2030
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 15, 2026
Sites
1 site added, 12 sites removed
Show site
  • Ohio Health Research Institute · Columbus, United States
Show 12 removed
  • Valley Cancer Associates · Harlingen, United States
  • Houston Methodist Hospital · Houston, United States
  • Markhot Ferenc Oktato Korhaz · Eger, Hungary
  • Ulsan University Hospital · Ulsan, South Korea
  • Gyeongsang National University Hospital · Jinju, South Korea
  • Jeonbuk National University Hospital · Jeonju, South Korea
  • Daegu Catholic University Medical Center · Daegu, South Korea
  • Samsung Medical Center · Seoul, South Korea
  • Hospital Universitario Miguel Servet · Zaragoza, Spain
  • Changhua Christian Hospital CCH · Changhua, Taiwan
  • Hualien Tzu Chi Medical Center · Hualien City, Taiwan
  • Chang Gung Memorial Hospital Linkou Branch · Taoyuan, Taiwan
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Recruiting→Active, not recruiting
    1 site added, 12 sites removed
    Show site
    • Ohio Health Research Institute · Columbus, United States
    Show 12 removed
    • Valley Cancer Associates · Harlingen, United States
    • Houston Methodist Hospital · Houston, United States
    • Markhot Ferenc Oktato Korhaz · Eger, Hungary
    • Ulsan University Hospital · Ulsan, South Korea
    • Gyeongsang National University Hospital · Jinju, South Korea
    • Jeonbuk National University Hospital · Jeonju, South Korea
    • Daegu Catholic University Medical Center · Daegu, South Korea
    • Samsung Medical Center · Seoul, South Korea
    • Hospital Universitario Miguel Servet · Zaragoza, Spain
    • Changhua Christian Hospital CCH · Changhua, Taiwan
    • Hualien Tzu Chi Medical Center · Hualien City, Taiwan
    • Chang Gung Memorial Hospital Linkou Branch · Taoyuan, Taiwan
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06072131
Responsible party
Sponsor
First posted
Oct 10, 2023
Start date
Oct 4, 2023
Primary completion
Jul 2030 (estimated)
Completion
Nov 2030 (estimated)
Last update
Oct 15, 2026

Study contacts

Uma Srinivas Atmuri, MPharm, MS
study director · Acrotech Biopharma Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Belinostat · Pralatrexate · Cyclophosphamide · Doxorubicin · Vincristine · Prednisone

Start the discussion